Director/PDMR Shareholding

AstraZeneca PLC
02 April 2007

Dealing by Directors

Companies Act 1985 Sections 324/329



Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rules DR 3.1.2R



We hereby inform you that on 30 March 2007 the following Directors of
AstraZeneca PLC were granted options under the AstraZeneca Share Option Plan
over the Company's USD0.25 Ordinary Shares.


                    Number of shares over
                    which option is
                    granted               Exercise price per  Period when          Total number of shares
                                          share               exercisable          under option
Name of Director


D R Brennan         128,462               2744p               30.3.10-29.3.17      See below


J R Symonds         60,349                2744p               30.3.10-29.3.17      423,769


J S Patterson       44,142                2744p               30.3.10-29.3.17      236,716



The options will become exercisable on 30 March 2010 subject to certain
performance conditions.  The conditions, which will not be subject to any
retesting, are that the earnings per share of the Company must increase by the
increase in the UK Retail Prices Index plus 5% per annum on average over three
years, and that no significant unforeseen event has taken place which, in the
reasonable opinion of the Remuneration Committee, has resulted in major
reputational damage to AstraZeneca, and the circumstances of which are
exceptional enough to justify the option not vesting and becoming exercisable.
Failure to satisfy either or both of these conditions will result in the lapse
of the option in its entirety.



David R Brennan, a Director of the Company, has previously received grants of
options over the Company's American Depositary Shares (ADSs).  One ADS equals
one Ordinary Share.  Following the grant of options referred to above, David
Brennan has options over 239,103 Ordinary Shares and 355,246 ADSs.





G H R Musker

Company Secretary

2 April 2007




                      This information is provided by RNS
            The company news service from the London Stock Exchange